EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu

Dow Jones

Oct 29, 2024

By Sabela Ojea

Shares of EyePoint Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema.

The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year.

The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial.

Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health.

The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

October 28, 2024 12:00 ET (16:00 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2479436396"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479436396\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2479436396?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479436396","market":"fut","top_or_hot":-1,"title":"EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema. \n</p>\n<p>\n  The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year. \n</p>\n<p>\n  The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial. \n</p>\n<p>\n  Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health. \n</p>\n<p>\n  The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2024 12:00 ET (16:00 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-10-29 00:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema. \n</p>\n<p>\n  The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year. \n</p>\n<p>\n  The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial. \n</p>\n<p>\n  Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health. \n</p>\n<p>\n  The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2024 12:00 ET (16:00 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EYPT","symbol_name":"EyePoint","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479436396","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479436396","pubTimestamp":1730131200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of EyePoint Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema.The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year.The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial.Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health.The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EYPT":"EyePoint"},"translate_title":"Duravyu临床试验数据积极，EyePoint Pharmaceuticals股价上涨35%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYPT":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of EyePoint Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema. \n\n\n  The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year. \n\n\n  The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial. \n\n\n  Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health. \n\n\n  The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2024 12:00 ET (16:00 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}